NFKB1 and inflammatory bowel disease: Also consistent with our in vitro results, both IL-1β-induced NF-κB and MAPK signaling (Figure 4B), and cytokine secretion (Figure 4C), were reduced in MDMs from rs7554511 CC IBD risk carriers.